perseus proteomics(PPMX)品牌介绍

浏览量：1935

perseus proteomics(PPMX)

品牌简介

本公司是在东京大学先进科学技术研究中心系统生物学和医学实验室(LSBM)开发的蛋白质表达和抗体生成技术的基础上成立的，旨在针对通过转录组分析确定的诊断和治疗靶点的抗体的医学应用。自成立以来，我们一直从事抗癌症和其他疾病的抗体药物“种子”的发现和相关的研究和开发活动。我们将动物免疫法与LSBM提供的膜蛋白表达技术相结合，高效地获得了高亲和力抗体，这是以往难以实现的。我们还拥有世界上多样性最大的噬菌体抗体文库和专利筛选技术，可应用于疾病细胞的药物靶点发现和同时鉴定不同于传统动物免疫方法获得的高功能抗体。我们技术的一个显著特点是将这两种抗体技术与“种子”发现技术相结合，获得满足医疗需求的抗体药物的“种子”。此外，作为一家起源于东京大学的风险投资公司，我们的使命是通过与许多学术机构的合作，进一步扩大最新药物发现的网络。

Our company was established based on the technologies of protein expression and antibody generation, which were developed by the Laboratories for Systems Biology and Medicine (LSBM) of the Research Center for Advanced Science and Technology at the University of Tokyo, aiming at the medical application of antibodies against the diagnostic and therapeutic targets identified through transcriptome analysis. Since inception, we have been engaging in the discovery of “seeds” of antibody drugs against cancer and other diseases and related activities for research and development. We efficiently obtained high-affinity antibodies by combining the animal immunization method with the expression technology provided by LSBM for the expression of membrane proteins, which has been difficult to achieve. We also have phage antibody libraries with the world’s largest diversity and a patented screening technology, which can be applied to drug target discovery in diseased cells and simultaneous identification of highly functional antibodies with characteristics different from those obtained by the conventional animal immunization method. A distinctive feature of our technology is to combine these two antibody technologies and the “seeds” discovery technology to obtain “seeds” of antibody drugs to meet medical needs. In addition, as a venture company originated from the University of Tokyo, we have the mission of further broadening the network for the latest drug discovery through collaboration with many academic institutions.